Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8 T cells.

Front Immunol

Laboratório de Virologia Básica e Aplicada, Instituto de Ciências Biológicas, Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Published: December 2023

Introduction And Methods: In this present work, coronavirus subfamilies and SARS-CoV-2 Variants of Concern (VOCs) were investigated for the presence of MHC-I immunodominant viral peptides using in silico and tools.

Results: In our results, HLA-A*02 haplotype showed the highest number of immunodominant epitopes but with the lowest combined prediction score. Furthermore, a decrease in combined prediction score was observed for HLA-A*02-restricted epitopes when the original strain was compared to the VOCs, indicating that the mutations on the VOCs are promoting escape from HLA-A2-mediated antigen presentation, which characterizes a immune evasion process. Additionally, epitope signature analysis revealed major immunogenic peptide loss for structural (S) and non-structural (ORF8) proteins of VOCs in comparison to the Wuhan sequence.

Discussion: These results may indicate that the antiviral CD8 T-cell responses generated by original strains could not be sufficient for clearance of variants in either newly or reinfection with SARS-CoV-2. In contrast, N epitopes remain the most conserved and reactive peptides across SARS-CoV-2 VOCs. Overall, our data could contribute to the rational design and development of new vaccinal platforms to induce a broad cellular CD8 T cell antiviral response, aiming at controlling viral transmission of future SARS-CoV-2 variants.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656734PMC
http://dx.doi.org/10.3389/fimmu.2023.1229712DOI Listing

Publication Analysis

Top Keywords

hla-a*02-restricted epitopes
8
sars-cov-2 variants
8
combined prediction
8
prediction score
8
vocs
5
surveillance sars-cov-2
4
sars-cov-2 immunogenicity
4
immunogenicity loss
4
loss immunodominant
4
immunodominant hla-a*02-restricted
4

Similar Publications

HLA-A02 restricted T-cell cross-reactivity to a microbial antigen.

J Immunotoxicol

December 2024

Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Molecular mimicry has been proposed to be a possible mechanism of induction of autoimmunity. In some cases, it is believed that such events could lead to a disease such as Type 1 diabetes (T1D). One of the primary MHC-I epitopes in the non-obese diabetic (NOD) mouse model of T1D has been identified as a peptide from the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) protein.

View Article and Find Full Text PDF

Chemorefractory ovarian cancer has limited therapeutic options. Hence, new types of treatment including neoantigen-specific immunotherapy need to be investigated. Neoantigens represent promising targets for personalized cancer immunotherapy.

View Article and Find Full Text PDF

T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell.

Front Immunol

August 2020

Biomarkers of Infection Related Diseases Beijing Key Laboratory, Beijing You'An Hospital, Capital Medical University, Beijing, China.

To test the safety and efficacy of a T cell therapy targeting HLA-A02 restricted HIV antigen epitopes. This was a prospective open label clinical trial, which enrolled 28 HIV+ participants and 24 of them finished the trial. The study was publicly registered at Chinese Clinical Trial Registry, www.

View Article and Find Full Text PDF

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Mol Ther

June 2018

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA; Cancer Center, Department of Pediatrics, The George Washington University, Washington, DC 20037, USA. Electronic address:

The Berlin Patient represents the first and only functional HIV cure achieved by hematopoietic stem cell transplant (HSCT). In subsequent efforts to replicate this result, HIV rebounded post-HSCT after withdrawal of antiretroviral therapy. Providing HIV-specific immunity through adoptive T cell therapy may prevent HIV rebound post-HSCT by eliminating newly infected cells before they can seed systemic infection.

View Article and Find Full Text PDF

Human JC and BK polyomaviruses (JCV/BKV) can establish a latent infection without any clinical symptoms in healthy individuals. In immunocompromised hosts infection or reactivation of JCV and BKV can cause lethal progressive multifocal leukoencephalopathy (PML) and hemorrhagic cystitis, respectively. Vaccination with JCV/BKV derived antigen epitope peptides or adoptive transfer of virus-specific T cells would constitute an elegant approach to clear virus-infected cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!